Pharma and biotech, where a director buy often lands close to trial or regulatory news and the price history around it is worth reading carefully.
7 disclosed directors purchases across 6 health care companies in the last twelve months, worth £435k. The median buy has returned +9.9% against the market since it was disclosed.
7 buys · £435k · 6 companies · 7 directors · median alpha +9.9%
63% of that value is HIK alone.
| Company | Value bought | Buys |
|---|---|---|
| Hikma Pharmaceuticals (HIK) | £273k | 2 |
| One Health Group PLC (OHGR) | £100k | 1 |
| AOTI, INC. (DI) (Regs, Cat 3) (AOTI) | £30k | 1 |
| Optima Health (OPT) | £20k | 1 |
| Okyo Pharma Limited NPV (OKYO) | £8k | 1 |
| Ixico (IXI) | £4k | 1 |
Rolling twelve months of disclosed purchases. Median alpha is measured against the market from the disclosure-day close — the first price a reader could have paid — not from the insider's own entry, and is marked to the latest cached close. Past performance is not a reliable indicator of future results.